BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180319
DTEND;VALUE=DATE:20180321
DTSTAMP:20260515T083502
CREATED:20171023T082959Z
LAST-MODIFIED:20171023T084059Z
UID:3576-1521417600-1521590399@www.pharmajournalist.com
SUMMARY:20th Annual Superbugs & Superdrugs
DESCRIPTION:Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities\, SMi presents the 20th annual Superbugs &Superdrugs conference which will return to Central London on 19th and 20th March 2018. \nThe threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders\, drug discovery specialists and government bodies such as MHRA and DNDi. \nFEATURED SPEAKERS INCLUDE: \n– Richard Bax\, Senior Partner\, TranScrip Partners\n– Lloyd Czaplewski\, Director\, Chemical Biology Ventures\n– Mair Powell\, Senior clinical assessor\, MHRA\n– Jean-Pierre Paccaud\, Director of Business Development at GARDP\, Drugs for Neglected Diseases initiative (DNDi)\n– Conrad Lichtenstein\, CSO\, Nemesis bioscience\n– David Brown\, Managing Director and Founder\, Alchemy Biomedical Consulting\n– Domingo Gargallo-Viola\, Chief Scientific Officer\, ABAC Therapeutics\n– John George\, CSO\, Oppilotech\n– Larry Sutton\, Scientific Founder\, Gladius Pharmaceuticals\n– Kathy Talkington\, Project Director\, Pew charitable trusts\n– David Cook\, Chief Scientific Officer\, Blueberry Therapeutics\n– William Weiss\, Director of Pre-Clinical Services\, University of North Texas Health Science Center\n– Cara Cassino\, Chief Medical Officer\, ContraFect\n– Stephen Barat\, Head of Pre-Clinical and Early Clinical Development\, SCYNEXIS Inc \nWHATS ON THE AGENDA FOR 2018? \n– Analyze the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR\n– Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress\n– Learn about regulatory pathways for the registration of new antimicrobial agents\n– Evaluate the latest incentives and funding solutions to spur drug discovery\n– Explore novel alternatives to antibiotics currently in development \nTo register visit www.superbugssuperdrugs.com/pjournalist \nFor enquires contact the team on +44 (0)207 827 6000 or email events@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/20th-annual-superbugs-superdrugs/
LOCATION:Copthorne Tara Hotel\, Kensington\, London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:events@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180319
DTEND;VALUE=DATE:20180321
DTSTAMP:20260515T083502
CREATED:20171031T010129Z
LAST-MODIFIED:20171031T044056Z
UID:3637-1521417600-1521590399@www.pharmajournalist.com
SUMMARY:12th annual Paediatric Clinical
DESCRIPTION:SMi is pleased to present the return of their 12th annual Paediatric Clinical Trials Conference taking place on 19th – 20th March 2018\, London\, UK. \n \nClinical trials in paediatric populations still pose several challenges and often many studies remain un- published. 10 years on from the introduction of EU Paediatric Investigation Plans (PIPs) there are still many lessons to be learned about the planning and execution of trials which should be tailored around the needs of children. Recent advancements in immuno-oncology research has led to an increase in clinical trials to treat cancer in children and adolescents. Greater emphasis has also been placed on pain-free administration of drugs in the bid to increase vaccination uptake and access to medicines. \nJoin us as we discuss current clinical trials and the innovative digital technology being used to improve clinical recruitment and retention as well as improve the quality of data being collected. leading industry experts will be looking at how to work within regulations and foster the involvement of young people in their care. We will also be looking at the planning and executing a paediatric clinical trial and the ways this can vary according to region. We will be exploring the complexities of paediatric drug formulation and helping you determine clinical endpoints. \nReasons to attend Paediatric Clinical Trials 2018 \n– Regulatory keynote from the MHRA – The UK’s Early Access to Medicines Scheme (EAMS) and how this scheme benefits paediatric patients\n– Hear from Amgen and Roche as they give exclusive case studies on new approaches to recruitment\, retention\, and clinical trial design for rare diseases\n– Pfizer and Barcelona Children’s Hospital will be exploring how advancements in technology are facilitating improved clinical trials and data collection for paediatric drug development\n– AstraZeneca will be reviewing and discussing paediatric clinical trial Legislation in the EU and US.\n– There will be an exciting panel with the likes of GSK\, Roche and regulatory bodies debating challenges and opportunities 10 years on from paediatric regulation in the EU and potential changes on the horizon\n– There will be multiple pharmaceutical companies (UCB\, Sanofi and GSK) debating scenarios where data extrapolation and government incentives might increase access to medicines in paediatric populations.\n– Discover how to optimise your approach to clinical success through global collaboration being discussed by Takeda
URL:https://www.pharmajournalist.com/event/12th-annual-paediatric-clinical/
LOCATION:Copthorne Tara Hotel\, London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:kwilliams@smi-online.co.uk
END:VEVENT
END:VCALENDAR